Pathios Therapeutics

OverviewSuggest Edit

Pathios Therapeutics is a biotech company focused on the development of therapies for autoimmune diseases and cancer. It is engaged in a fully-enabled drug discovery program to identify novel small-molecule modulators of GPR65 with expected utility in a range of autoimmune conditions as well as in certain cancers. The company is also interested in acid-sensing receptors in the immune system and their potential exploitation as targets for bringing about therapeutic benefits in a range of diseases.
TypePrivate
Founded2017
HQOxford, GB
Websitepathiostherapeutics.com

Latest Updates

Employees (est.) (Oct 2021)11
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Pathios Therapeutics Office Locations

Pathios Therapeutics has an office in Oxford
Oxford, GB (HQ)
Belsyre Court, 57 Woodstock Rd
Show all (1)

Pathios Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2017

Pathios Therapeutics total Funding

$8.8 m

Pathios Therapeutics latest funding size

$8.8 m

Time since last funding

2 years ago

Pathios Therapeutics investors

Pathios Therapeutics's latest funding round in December 2019 was reported to be $8.8 m. In total, Pathios Therapeutics has raised $8.8 m
Show all financial metrics

Pathios Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Pathios Therapeutics Online and Social Media Presence

Embed Graph

Pathios Therapeutics News and Updates

Pathios Therapeutics Presents Preclinical In Vivo Proof of Concept Data for small molecule GPR65 inhibitor in human PDX cancer model

OXFORD, United Kingdom, July 7, 2021 /PRNewswire/ -- Pathios Therapeutics Limited ("Pathios"), an innovative biotech company focused on the development of first-in-class therapies for cancer, today announced the presentation of preclinical data establishing in vivo proof of concept for...

Pathios Therapeutics Blogs

Pathios Therapeutics presents preclinical in vivo proof of concept data for small molecule GPR65 inhibitor in human PDX cancer model

Data highlights the ability of GPR65 inhibition to bring about a robust Type I/II interferon (IFN) gene signature and reduce tumor burden in a renal cell carcinoma (RCC) PDX model. This demonstrates the promise of Pathios’ Macrophage Conditioning approach in reversing the immunosuppressive polarizat…

Pathios Therapeutics boosted by award of significant Innovate UK funding

Pathios Therapeutics will team up with researchers at The University of Oxford to accelerate cancer immunotherapies targeting GPR65 on immunosuppressive macrophages OXFORD, UK 8th March 2021: Pathios Therapeutics Limited (“Pathios”), an innovative biotech company focused on the development of first-…

Pathios Therapeutics Frequently Asked Questions

  • When was Pathios Therapeutics founded?

    Pathios Therapeutics was founded in 2017.

  • How many employees does Pathios Therapeutics have?

    Pathios Therapeutics has 11 employees.

  • Who are Pathios Therapeutics competitors?

    Competitors of Pathios Therapeutics include OncoQuest, Tiltan Pharma and Cantargia.

  • Where is Pathios Therapeutics headquarters?

    Pathios Therapeutics headquarters is located at Belsyre Court, 57 Woodstock Rd, Oxford.

  • Where are Pathios Therapeutics offices?

    Pathios Therapeutics has an office in Oxford.

  • How many offices does Pathios Therapeutics have?

    Pathios Therapeutics has 1 office.